| | | |

Cracking the Code: New Mathematical Model for Cancer Screening to Catch Some Mesotheliomas Sooner

Cracking the Code: New Mathematical Model for Cancer Screening to Catch Some Mesotheliomas Sooner

Cancers, such as malignant mesothelioma, are one of the leading causes of death. Yet mortality could be reduced by detecting malignant tumors earlier so that treatment is started earlier at a less aggressive stage. A team of American data scientists recently “cracked the code” of cancer screenings.

Cancer screenings are expensive and it can be difficult to know who and when to give screening. The tradeoff between the cost and the benefit of cancer screening is an ongoing challenge.

A new study in PLOS Computational Biology describes a new mathematical model to help clinicians decide whom to screen and when. This is a big step forward in catching some mesotheliomas earlier.

Early Diagnosis for Mesothelioma is Key

Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed. Former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos-caused cancers.

As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier.

Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.

Cracking the Code for Cancer Screening

A team of data scientists from the Dana-Farber Cancer Institute in Boston wanted to find a better way to evaluate cancer screening strategies. They wanted to create an optimal cancer screening protocol.

For most cancer types, including mesothelioma, a sensitive cancer screening is not available. Cancer screening takes time and is very expensive. And in some cases, it does not prolong patient survival.

The Boston team was determined to find a way to maximize the benefits of cancer screening. They used mathematical modeling to quantify the benefits of screening based on clinical factors. Patient age at diagnosis, rate of cancer tumor progression, and treatment outcomes were included.

Others have tried to solve this problem. But the models created here were different. These models were based on the theory of queuing networks which tracks disease progression over time.

Useful Toolbox through Simple Examples

Justin Dean, PhD of the Dana-Farber Cancer Institute in Boston states, “Our aim is to illustrate an alternative and potentially useful toolbox through simple examples.”

The Boston team of data scientists created a mathematical model for cancer screening. This model estimates the costs and benefits of cancer screening, including mesothelioma.

This new queuing approach is a potentially useful alternative to the traditional modeling approaches. This new approach provides more detailed results. It can be widely applied to estimate the costs and benefits of cancer screening strategies.

Source:

Dean, Justin, Evan Goldberg, and Franziska Michor. “Designing optimal allocations for cancer screening using queuing network models.” PLOS Computational Biology 18, no. 5 (2022): e1010179. https://doi.org/10.1371/journal.pcbi.1010179

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • |

    Mesothelioma Case Shows Danger of Accidental Asbestos Exposure

    A mesothelioma case in Birmingham, England is a dramatic illustration of the very real danger of hidden asbestos. The widow of a physician who died of mesothelioma last year at the age of 51 claims her husband was exposed to asbestos just walking to and from his medical classes. Monisha Coelho believes that exposed asbestos insulation in the underground hallways that connect the University of Birmingham to buildings on the Queen Elizabeth Hospital campus triggered Dr. Ian Pardoe’s mesothelioma. In an article in the Birmingham Mail, Coelho explained how her husband decided how and where the deadly exposure had occurred. “Ian thought long and hard about where he might have come into contact with asbestos,” Coelho told the paper. “He…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • |

    Short-term Asbestos Exposure Triggers Mesothelioma

    The recent death of a British man from mesothelioma is evidence of the destructive power of asbestos – even when exposure is short.  A British newspaper reports that Welwyn resident Roger Beale first began experiencing a classic symptom of mesothelioma, shortness of breath, nearly 4 years ago. Beale first noticed the problem while walking up stairs. After a chest X-ray, Beale’s symptoms were attributed to a chest infection.  But when his symptoms continued to worsen, Beale sought medical care again in January, 2010 and was diagnosed with pleural mesothelioma, an intractable cancer of the lung lining that is almost always caused by exposure to asbestos. By November of 2010, Beale’s shortness of breath had gotten worse, despite regular monitoring and…

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…